US Markets: Tech Stocks Drag S&P 500 and Nasdaq Lower Amid Iran Talks

Wall Street experienced a divergent trading session on Monday as megacap technology stocks pulled the S&P 500 and Nasdaq into the red, while the Dow Jones Industrial Average managed a modest gain. Investors remained on high alert, balancing geopolitical shifts in U.S.-Iran negotiations against growing skepticism regarding massive AI infrastructure spending.

Tech Giants and SpaceX Weigh on Nasdaq

The Nasdaq Composite bore the brunt of the market's weakness, shedding 339.67 points, or 1.28%, to close at 26,178.26. This decline was primarily driven by a sharp sell-off in megacap tech stocks, including Alphabet, Meta, Amazon, and Microsoft. Analysts noted that the tech sector remains highly sentiment-driven, often moving in unison.

Adding to the pressure on the Nasdaq was a significant tumble in SpaceX shares. The Elon Musk-led company, which launched its first-ever debt offering on Monday, reported having approximately $100.8 billion in cash and cash equivalents as of June 19. While AI optimism has fueled recent rallies, investors are increasingly questioning the astronomical infrastructure expenditures by hyperscalers. All eyes now turn to Micron Technology’s quarterly results this Wednesday to gauge the sector's health.

Geopolitics and Energy Markets

In contrast to the equity volatility, oil prices saw a decline following reports of progress in U.S.-Iran negotiations. Mediators indicated that officials in Switzerland made "great progress" during the first round of talks, establishing a 60-day roadmap toward a final deal. Although tensions persist regarding Lebanon and the Strait of Hormuz, the potential for stability has provided a catalyst for lower energy prices, which generally benefits both consumers and businesses.

Divergent Performance: Dow and Biotech Gains

While tech struggled, the Dow Jones Industrial Average rose 162.36 points, or 0.29%, to end at 51,727.06, supported by strength in the healthcare and industrial sectors. A notable mover in the biotech space was Apogee Therapeutics, which saw its shares jump following news that AbbVie would acquire the company in a cash deal valued at $10.9 billion.

The Federal Reserve and Inflation Outlook

The broader market sentiment is also being shaped by expectations surrounding the Federal Reserve. With the appointment of Kevin Warsh as the new Chair, market participants are bracing for a more "hawkish" stance focused on price stability. This outlook has contributed to a rise in U.S. Treasury yields, placing downward pressure on stocks.

Investors are now looking toward Thursday’s Personal Consumption Expenditures (PCE) data—the Fed's preferred inflation gauge. A reading higher than expected could reinforce the need for aggressive monetary policy, especially as markets currently price in a 25-basis-point rate hike for September.

Key Takeaways

  • Tech Volatility: Megacap stocks like Alphabet and Meta dragged the Nasdaq down by 1.28%, fueled by concerns over AI spending levels.
  • Geopolitical Shift: Potential progress in U.S.-Iran talks has helped stabilize energy prices, offering a boost to broader economic sentiment.
  • Inflation Watch: The upcoming PCE data will be critical in determining if the Federal Reserve follows a hawkish path to combat inflation.